Brought to you by 
BioMerieux, Genome to develop diagnostic products
15 Feb 2000
Executive Summary
Genome Therapeutics and bioMerieux (diagnostic systems and reagents for infectious diseases and industrial applications) will develop, manufacture, and sell in vitro diagnostic products for human clinical and industrial applications. BioMerieux will pay a technology access fee up front, make a $3.75mm up-front equity investment in GT, fund research for at least four years, and pay sales royalties.
Deal Industry
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioMerieux, Genome to develop diagnostic products
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice